July 14, 2020   English | عربي
Add to Twitter
Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19
• Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) being developed to treat infected, high-risk individuals with COVID-19

• Exploring the potential to repurpose marketed products and molecules to potentially treat COVID-19
News Agencies Feed